Biogen, INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$73Mgeneral payments (2019-2025)
$2.1Mresearch payments (2019-2025)
40,411clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $16M
2020 $11M
2021 $12M
2022 $11M
2023 $11M
2024 $5.0M
2025 $6.4M

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Neurology (Psychiatry & Neurology) $46M
Internal Medicine $4.6M
Neurology With Special Qualifications In Child Neurology $2.9M
Medical Oncology $2.7M
Family $1.7M
Psychiatry $1.4M

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Steven Ryder Westport, CT Internal Medicine $3,887,797.49
Stephen Sherwin San Francisco, CA Medical Oncology $2,735,213.82
Daniel Bandari Newport Beach, CA Neurology (Psychiatry & Neurology) $785,935.12
Regina Berkovich West Hollywood, CA Neurology (Psychiatry & Neurology) $784,014.78
Anoopum Gupta Pittsburgh, PA Neurology (Psychiatry & Neurology) $588,325.56
Kenneth Mankowski Columbus, OH Neurology (Psychiatry & Neurology) $562,391.61
William Flanders Atlanta, GA Public Health & General Preventive Medicine $515,868.39
Perry Shieh Los Angeles, CA Neurology (Psychiatry & Neurology) $507,085.10
Mark Tullman Saint Louis, MO Neurology (Psychiatry & Neurology) $477,369.51
Bruce Hughes Des Moines, IA Neurology (Psychiatry & Neurology) $470,683.06

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.